Company News

Company News

Uncategorized

Polaris Group Has Entered Into An Agreement With The University Of California,Irvine(UCI) To Develop A Universal Influenza And Coronavirus Vaccine.

Polaris Group has entered into an agreement with the University of California,Irvine(UCI) to develop a universal influenza and coronavirus vaccine.

Read More
Uncategorized

Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 in Metastatic Uveal Melanomas

SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI‑PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas. The results were presented by Dr. Peter Szlosarek from Barts Cancer Center in the UK (abstract No.2589) at the American Society Clinical Oncology’s 2018 annual meeting.

Read More
Uncategorized

Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board

Read More
Uncategorized

Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board

SAN DIEGO, July 9, 2018 — Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board.

Read More
Scroll to Top